No relief for India as US retains it on IP ‘Priority Watch List’
USTR Section 301 report on IP cites concerns over potential threat of patent revocations; pharma sector remains a focus area
USTR Section 301 report on IP cites concerns over potential threat of patent revocations; pharma sector remains a focus area
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
